Quick Summary — CDXS scores higher on quality with 6.1/10 vs CBIO's 5.3/10. CBIO trades at $17.00 while CDXS trades at $2.69. Both analyzed daily using SEC EDGAR data across 13 institutional models.
CDXS scores higher with a 6.1/10 quality rating vs CBIO's 5.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
At $17.00, CBIO trades +54.9% above its Bayesian DCF fair value of $7.68, while CDXS at $2.69 trades +86.3% above its estimate of $0.37. CDXS shows a wider gap between price and intrinsic value.
CBIO earns a Quality of Company score of 5.3/10 compared to CDXS's 6.1/10. The scores are closely matched, indicating similar fundamental quality profiles. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.
CBIO carries a SAFE value trap risk (12/100) while CDXS shows SAFE risk (20/100). Both companies show manageable value trap risk, suggesting their current valuations are not artificially depressed by fundamental deterioration.
Both CBIO and CDXS operate in Biotechnology, which has 566 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).
11 hidden models compare CBIO vs CDXS differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.
Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day
See All 13 Models — $0.90/dayWe don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.